Partner News | Published: Monday, October 19, 2026
MedAxiom, the cardiovascular community’s premier source for organizational performance solutions, is excited to announce an industry partnership with Penumbra, Inc., a developer of technologies that address challenging medical conditions, including venous thromboembolism (VTE), pulmonary embolism (PE), acute myocardial infarction (AMI), acute limb ischemia and ischemic stroke.
Penumbra’s broad portfolio includes computer-assisted vacuum thrombectomy (CAVT™), which is designed to remove blood clots from head to toe with an emphasis on speed, safety and simplicity. The company supports healthcare providers, hospitals and clinics in more than 100 countries as they care for patients with conditions including VTE, PE, AMI, acute limb ischemia and ischemic stroke.
“We are pleased to welcome Penumbra to the MedAxiom community. Venous thromboembolism represents a significant challenge for cardiovascular programs, particularly as organizations work to identify at-risk patients and establish consistent approaches to diagnosis, risk stratification and treatment,” said Joe Sasson, PhD, MedAxiom’s executive vice president of Ventures and chief commercial officer. “Penumbra’s experience developing technologies to address blood clots, along with its knowledge of the evolving treatment landscape, will bring valuable insights to the MedAxiom community as our members work to improve care pathways and outcomes for patients with VTE and PE.”
About MedAxiom
MedAxiom, an American College of Cardiology Company, is the cardiovascular community’s premier source for organizational performance solutions. MedAxiom is transforming cardiovascular care by combining the knowledge and power of hundreds of cardiovascular organization members, thousands of administrators, clinicians and revenue cycle experts, and dozens of industry partners. Through the delivery of proprietary tools, smart data and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience.
About Penumbra
Penumbra, Inc., the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.
By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.
